A Study of Orelabrutinib in Patients With AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder
Status:
Not yet recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
Neuromyelitis optica spectrum disorder (NMOSD) is a chronic inflammatory demyelinating
autoimmune disease of the central nervous system. NMOSD is a highly relapsing, severely
disabling disease. AQP4-IgG positive NMOSD is related to a specific aquaporin 4 antibody
(AQP4 IgG) produced by mature B cells. BTK is a key kinase in B cell receptor signal
transduction pathway. Abnormal activation of BTK related signaling pathway can lead to
autoantibody production and autoimmune diseases. Therefore, BTK can be developed as a new
target for autoimmune diseases.